MKS Instruments (MKSI) — 2026Q2 FY2026 Earnings Call Analysis

Growing 50% vs WFE at 25%, and CEO Knows It Reverses

They are bursting at capacity and the CEO explicitly refused to raise prices when asked directly.

Thesis: MKS is executing a classic ramp-cycle beat-and-raise with real cash conversion ($188M FCF, 15% of revenue) and one full turn of deleveraging in twelve months. The semi business growing 50%+ against WFE at 25-30% is mathematically unsustainable by the CEO's own admission, but the chemistry equipment annuity with 6-9 month lead times and down payments gives 18-month visibility that decouples near-term revenue from WFE beta. The risk is cycle position, not execution.

Verdict: LONG — Conviction: MEDIUM

Catalyst: Guangzhou second factory online Q3 2027 removes chemistry equipment capacity constraint, converting low-margin equipment sales into high-margin recurring chemistry attach on the 24-30 month lag management described.

Key Risk: WFE normalization while startup costs, China decline, and unfavorable mix persist. CEO stated outright: 'at some point we will meet WFE and on the downturn it reverses.' The gap between 50% and 25% closes in both directions.

The Tell: Lee volunteered unprompted: 'At some point, we will meet WFE just because the ramp will peak, and then on the downturn it reverses.' He wasn't asked about downside risk. He volunteered cycle awareness in the middle of a beat-and-raise, suggesting he sees the clock ticking on this ramp cycle even while planning capacity expansion into it.

Detected Patterns

Beat Above Buy-Side Whispers: EPS $3.30 beat high end of guidance by 86% YoY growth. Q3 guide of $1.35B with op margin expanding to 26.3% pushes above prior guidance range across every segment. All three markets accelerating simultaneously.
Backlog Fortress: Chemistry equipment orders 'moved another level above' elevated levels with down payments giving visibility through 2027. CFO confirmed 6-9 month lead times requiring customer deposits, not soft orders.
Capital Conviction: Doubling Guangzhou capacity, restarting Germany factory, CapEx at 4-5% of revenue, all while deleveraging from 4x to 3x on $188M quarterly FCF. Management is spending during the ramp, not extracting.
Bottleneck Removal Enabling Growth: Germany restarted to fill gap before Q3 2027 Guangzhou expansion. Management shipping every order despite being 'bursting at the seams.' New capacity unlocks higher-margin chemistry revenue on installed equipment base.

Friction Level: MODERATE_FRICTION — Both sides agree on strong execution and clean cash flow. Disagreement centers on whether 50%+ semi growth against WFE at 25-30% is structural outperformance or a cyclical spike that mean-reverts, and whether zero pricing power at full capacity undermines the bottleneck thesis.

Report not found

The report data is no longer available. Please return to the archive.

Growing 50% vs WFE at 25%, and CEO Knows It Reverses | Silicon Signal